Immatics NV (IMTX)
10.85
+0.04
(+0.37%)
USD |
NASDAQ |
May 02, 10:53
Immatics Cash from Investing (TTM): -33.98M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -33.98M |
| September 30, 2023 | -199.99M |
| June 30, 2023 | -191.97M |
| March 31, 2023 | -231.79M |
| December 31, 2022 | -221.24M |
| September 30, 2022 | -122.59M |
| June 30, 2022 | -30.40M |
| Date | Value |
|---|---|
| March 31, 2022 | 12.33M |
| December 31, 2021 | 8.866M |
| September 30, 2021 | 10.96M |
| June 30, 2021 | -43.27M |
| March 31, 2021 | 6.083M |
| December 31, 2020 | -18.21M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-231.79M
Minimum
Mar 2023
12.33M
Maximum
Mar 2022
-81.17M
Average
-33.98M
Median
Dec 2023
Cash from Investing (TTM) Benchmarks
| MorphoSys AG | -- |
| Affimed NV | -39.04M |
| InflaRx NV | -19.16M |
| BioNTech SE | -7.529B |
| CureVac NV | -59.76M |